Skip to main content
RNTX logo

Rein Therapeutics Inc. (RNTX) Stock Price & Analysis

Rein Therapeutics Inc. (RNTX) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.3369 (-8.38%), as of the Nov 20, 2026 trading session; market cap $29.1M.

Educational signal · not a buy or sell recommendation · How to read this

$0.3369 −$0.0308 (-8.38%) Market Cap $29.1M

Rein Therapeutics Inc. · RNTX · NASDAQ

Rein Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for cancer and other diseases.

Price as of Nov 20, 2026

Key Statistics

30 of 100

MoonshotScore v2 · Rein Therapeutics (RNTX)

Weak
Business Quality Thin (31)
Financial Safety Okay (53)
Valuation Bubble (4)
Growth Durability Fading (28)
Momentum Slipping (22)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, weak growth and an expensive valuation, though the balance sheet is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.

Earnings yield is the main valuation drag relative to sector peers.

  • EPS beat 0 of the last 4 reports
  • Altman Z -7.75 · Piotroski F 2

Holding back: weak fundamentals, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RNTX (58 recorded, newest six shown)
RecordedScoreBand
30Weak
30Weak
30Weak
30Weak
30Weak
30Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.3369
Change on the day-8.38%
52-week range$0.3369 – $2.10
Market capitalisation$29.1M—
Shares traded on the day668.6K

Price & events

Other perspectives

Council score for Rein Therapeutics (RNTX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Negative
Growth Durability Weak
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Rein Therapeutics (RNTX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Rein Therapeutics Inc. (RNTX) is listed on NASDAQ. It employs 10 people and is led by James Brian Windsor. The market values it at $29.1M.

2 · Latest results

What do the latest results show for Rein Therapeutics (RNTX)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$0-$6M-$0.06 (diluted)
Q2 FY2026$0-$6M-$0.21 (diluted)
Q1 FY2026$0-$6M-$0.19 (diluted)
Q4 FY2025$0-$32M-$1.26 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Rein Therapeutics (RNTX)?

Short answer

What is holding it back is weak fundamentals, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -7.75 · Piotroski F 2. Trailing ratios: ROA -24.6% · current ratio 6.57.

Data-derived red flags

  • Listing risk — at $0.3369 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -7.75 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 1 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Rein Therapeutics (RNTX)?

Short answer · as of

The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Rein Therapeutics compare with its peers?

Short answer

Rein Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.47 Nov 20, 2026$86.6M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Named competitor$166.53 Nov 19, 2026$207B72 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026
Alopexx, Inc. (ALPX) Same industry, near in market value$10.02 Nov 20, 2026$148M61 5-pillar Nov 18, 2026
Rein Therapeutics (RNTX) — this page$0.3369$29.1M30

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 3, 2026)
$6.00 – $6.00
Last captured analyst target (expired, captured Nov 3, 2026)
$6.00
Last captured median analyst target (expired, captured Nov 3, 2026)
$6.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated May 27, 2026

Transactions
2
Identified insiders
1
Purchases
2
Sales
0
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RNTX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RNTX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Rein Therapeutics (RNTX)?

Read these with our analysis →

Common Questions About RNTX

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for RNTX?

RNTX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is RNTX a good stock to buy?

Stock Expert AI does not rate RNTX buy, sell or hold. Rein Therapeutics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RNTX stock price today?

The last price recorded for Rein Therapeutics Inc. (RNTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RNTX price target?

The last analyst consensus price target we captured for Rein Therapeutics Inc. (RNTX), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

What are the key factors to evaluate for RNTX?

Rein Therapeutics Inc. (RNTX) holds a MoonshotScore in the low range. The company does not currently offer a dividend, consistent with its focus on reinvesting in research and development. Not financial advice.

How frequently does RNTX data refresh on this page?

RNTX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RNTX's recent stock price performance?

Rein Therapeutics Inc. (RNTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RNTX overvalued or undervalued right now?

Rein Therapeutics Inc. (RNTX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of RNTX?

Fractional-share availability for Rein Therapeutics Inc. (RNTX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.